| RS2509780649 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509782397 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509782416 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509782899 |
SLC12A6
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease, axonal |
| RS2509783000 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509785660 |
FDXR
|
Health Risk |
Pathogenic |
Auditory neuropathy-optic atrophy syndrome, Multiple mitochondrial dysfunctions syndrome 9b |
| RS2509787371 |
SNF8
|
Health Risk |
Pathogenic |
SNF8-associated disease, Neurodevelopmental disorder plus optic atrophy |
| RS2509788341 |
FDXR
|
Health Risk |
Pathogenic |
Multiple mitochondrial dysfunctions syndrome 9b, Multiple mitochondrial dysfunctions syndrome 9b |
| RS2509800523 |
SLC12A6
|
Health Risk |
Likely pathogenic |
— |
| RS2509802259 |
SLC12A6
|
Health Risk |
Likely pathogenic |
— |
| RS2509802539 |
SLC12A6
|
Health Risk |
Pathogenic |
— |
| RS2509802682 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509802792 |
SLC12A6
|
Health Risk |
Likely pathogenic |
— |
| RS2509803787 |
SLC12A6
|
Health Risk |
Likely pathogenic |
— |
| RS2509803879 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509804375 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509804742 |
SLC12A6
|
Health Risk |
Likely pathogenic |
— |
| RS2509808694 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509808876 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509809229 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509809254 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509810372 |
CANT1
|
Health Risk |
Pathogenic |
— |
| RS2509812481 |
CANT1
|
Health Risk |
Pathogenic |
— |
| RS2509812559 |
CANT1
|
Health Risk |
Pathogenic |
— |
| RS2509812786 |
CANT1
|
Health Risk |
Conflicting classifications of pathogenicity |
Desbuquois dysplasia 1, Epiphyseal dysplasia |
| RS2509813177 |
CANT1
|
Health Risk |
Pathogenic |
— |
| RS2509813194 |
CANT1
|
Health Risk |
Pathogenic |
— |
| RS2509813279 |
CANT1
|
Health Risk |
Pathogenic |
— |
| RS2509816766 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509816869 |
SLC12A6
|
Health Risk |
Pathogenic |
— |
| RS2509816917 |
SLC12A6
|
Health Risk |
Pathogenic |
— |
| RS2509816956 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509817001 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509817015 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509817358 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509817534 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509817742 |
SLC12A6
|
Health Risk |
Likely pathogenic |
— |
| RS2509820987 |
SLC12A6
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, axonal |
| RS2509821769 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509821779 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509828295 |
RBFOX1
|
Health Risk |
Likely pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2509832183 |
SLC12A6
|
Health Risk |
Likely pathogenic |
— |
| RS2509832575 |
SLC12A6
|
Health Risk |
Pathogenic |
— |
| RS2509832801 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509832921 |
SLC12A6
|
Health Risk |
Pathogenic |
— |
| RS2509832966 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509832995 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509833034 |
SLC12A6
|
Health Risk |
Pathogenic |
— |
| RS2509837404 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509837476 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509838414 |
FOXJ1
|
Health Risk |
Likely pathogenic |
Ciliary dyskinesia, primary |
| RS2509838550 |
FOXJ1
|
Health Risk |
Likely pathogenic |
FOXJ1-related disorder, FOXJ1-related disorder |
| RS2509846598 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509846608 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509847354 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509847517 |
SLC12A6
|
Health Risk |
Likely pathogenic |
— |
| RS2509863445 |
CAVIN1
|
Health Risk |
Likely pathogenic |
Congenital generalized lipodystrophy type 4, Congenital generalized lipodystrophy type 4 |
| RS2509875985 |
CAVIN1
|
Health Risk |
Likely pathogenic |
CAVIN1-related disorder, CAVIN1-related disorder |
| RS2509876602 |
CAVIN1
|
Health Risk |
Pathogenic |
Congenital generalized lipodystrophy type 4, Congenital generalized lipodystrophy type 4 |
| RS2509876910 |
CAVIN1
|
Health Risk |
Pathogenic |
Congenital generalized lipodystrophy, Congenital generalized lipodystrophy |
| RS2509887847 |
KCNJ16
|
Health Risk |
Pathogenic |
KCNJ16-related disorder, Hypokalemic tubulopathy and deafness |
| RS2509893598 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509893610 |
SLC12A6
|
Health Risk |
Likely pathogenic |
Agenesis of the corpus callosum with peripheral neuropathy, Agenesis of the corpus callosum with peripheral neuropathy |
| RS2509893730 |
SLC12A6
|
Health Risk |
Likely pathogenic |
— |
| RS2509907102 |
GCGR
|
Health Risk |
Pathogenic |
GCGR-related hyperglucagonemia, GCGR-related hyperglucagonemia |
| RS2509920625 |
GAS2L2
|
Health Risk |
Pathogenic |
Primary ciliary dyskinesia 3, Primary ciliary dyskinesia 3 |
| RS2509920970 |
KCNJ2
|
Health Risk |
Pathogenic |
Andersen Tawil syndrome, Andersen Tawil syndrome |
| RS2509921093 |
KCNJ2
|
Health Risk |
Likely pathogenic |
Cardiovascular phenotype, Cardiovascular phenotype |
| RS2509921216 |
KCNJ2
|
Health Risk |
Conflicting classifications of pathogenicity |
Andersen Tawil syndrome, Cardiovascular phenotype |
| RS2509932355 |
THOC1
|
Health Risk |
Pathogenic |
Hearing loss, autosomal dominant 86 |
| RS2509944883 |
TBCD
|
Health Risk |
Pathogenic |
— |
| RS2509949884 |
P4HB
|
Health Risk |
Likely pathogenic |
— |
| RS2509957512 |
SLC4A1
|
Health Risk |
Pathogenic |
— |
| RS2509958411 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509958522 |
SLC4A1
|
Health Risk |
Likely pathogenic |
Cryohydrocytosis, Cryohydrocytosis |
| RS2509958533 |
SLC4A1
|
Health Risk |
Pathogenic |
— |
| RS2509958666 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509958707 |
SLC4A1
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 4, Hereditary spherocytosis type 4 |
| RS2509958851 |
SLC4A1
|
Health Risk |
Pathogenic |
— |
| RS2509958853 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509958887 |
SLC4A1
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary spherocytosis type 4, Hereditary spherocytosis type 4 |
| RS2509960774 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509960878 |
SLC4A1
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2509960984 |
SLC4A1
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary spherocytosis type 4, Hereditary spherocytosis type 4 |
| RS2509960998 |
SLC4A1
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 4, Hereditary spherocytosis type 4 |
| RS2509961092 |
SLC4A1
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2509962459 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509962537 |
SLC4A1
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2509962539 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509962547 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509962553 |
SLC4A1
|
Health Risk |
Pathogenic |
— |
| RS2509962608 |
SLC4A1
|
Health Risk |
Pathogenic |
— |
| RS2509962645 |
SLC4A1
|
Health Risk |
Pathogenic |
— |
| RS2509962733 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509962737 |
SLC4A1
|
Health Risk |
Pathogenic |
— |
| RS2509962789 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509963578 |
SLC4A1
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2509964040 |
SLC4A1
|
Health Risk |
Likely pathogenic |
— |
| RS2509964054 |
SLC4A1
|
Health Risk |
Pathogenic |
— |
| RS2509964063 |
SLC4A1
|
Health Risk |
Pathogenic |
— |